Daiichi Sankyo and AstraZeneca Report P-III Trial (TROPION-Breast01) Results of Datopotamab Deruxtecan for Breast Cancer
Shots:
- The P-III trial evaluating datopotamab deruxtecan (TROP2 directed DXd ADC) vs CT in 700 patients with inoperable or metastatic HR+, HER2 low or negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer at sites in Asia, EU, North America, South America & Africa patients
- The results showed an improvement for the 1EPs of PFS. The safety profile was consistent with prior clinical trials in breast cancer with no new safety signals while all grade interstitial lung disease rates were low
- The results will be presented at an upcoming medical meeting and shared with regulatory authorities. Datopotamab deruxtecan is currently being studied in two additional P-III trials for breast cancer
Ref: Businesswire| Image: Daiichi Sankyo
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
